20th
April
2022
Resistell initiates a research project funded by an independent grant from Pfizer AG
Resistell, a TOP10 Swiss Start-up addressing the problem of speed in the diagnostics of antibiotic resistance, is pleased to announce they have initiated a research project to assess the applicability of Resistell’s antibiotic susceptibility test (AST) to a novel antibiotic. The project is funded by an independent grant from Pfizer AG.
15th
December
2021
Resistell announces completion of clinical pilot performance evaluation study
Run in close collaboration with the microbiologists and infectious diseases specialists at the Lausanne University Hospital (CHUV) in Switzerland, the goal of the ongoing clinical study is to assess the sensitivity, specificity, accuracy and time to result of Resistell AST compared to the gold standard methods used at CHUV, namely Kirby-Bauer disc diffusion test and automated Vitek2 system® (bioMérieux). The study focuses on patients admitted to CHUV with bacteremia or sepsis due to Gram-negative bacteria.
